An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma
Grünwald, Viktor; Eberhardt, Berit; Bex, Axel; Flörcken, Anne; Gauler, Thomas; Derlin, Thorsten; Panzica, Martin; Dürr, Hans Roland; Grötz, Knut Achim; Giles, Rachel H; von Falck, Christian; Graser, Anno; Muacevic, Alexander; Staehler, Michael
(2018) Nature Reviews. Urology, volume 15, issue 8, pp. 511 - 521
(Article)
Abstract
Bone is a major site of haematogenous tumour cell spread in renal cell carcinoma (RCC), and most patients with RCC will develop painful and functionally disabling bone metastases at advanced disease stages. The prognosis of these patients is generally poor and the treatment is, therefore, aimed at palliation. However, RCC-associated
... read more
bone metastases can be curable in select patients. Current data support a multimodal management strategy that includes wide resection of lesions, radiotherapy, systemic therapy, and other local treatment options, which can improve quality of life and survival. Nevertheless, the optimal approach for metastatic bone disease in RCC has not yet been defined and practical recommendations are rare. To improve the management and outcomes of patients with RCC and bone metastases, the International Kidney Cancer Coalition and the interdisciplinary working group on renal tumours of the German Cancer Society convened a meeting of experts with a global perspective to perform an unstructured review and elaborate on current treatment strategies on the basis of published data and expertise. The panel formulated recommendations for the diagnosis and treatment of patients with RCC and metastasis to the bone. Furthermore, the experts summarized current challenges and unmet patient needs that should be addressed in the future.
show less
Download/Full Text
Keywords: Journal Article, Review, Interdisciplinary Communication, Carcinoma, Renal Cell/diagnosis, Humans, Kidney Neoplasms/pathology, Combined Modality Therapy/standards, Bone Neoplasms/diagnosis, Consensus, Urology, Review, Research Support, Non-U.S. Gov't, Journal Article
ISSN: 1759-4812
Publisher: Nature Research
Note: Funding Information: This Expert Consensus Document was funded by the International Kidney Cancer Coalition (IKCC). The authors thank A. Luetke (medinform, Ratekau, Germany) for editorial support on behalf of the IKCC. Funding Information: V.G. has participated in advisory boards for Bristol Myer Squibb (BMS), Eisai, Ipsen, Novartis, Pfizer, and Roche, has received honoraria for compensation from BMS, Eisai, Ipsen, Novartis, Pfizer, and Roche, and has received travel grants from BMS, MSD Merck, Novartis, and Pfizer. B.E. has received honoraria and/or travel grants from Pfizer. Uronauten receives no grants from the pharmaceutical industry. A.B. has participated in advisory boards for BMS, Ipsen, Novartis, Pfizer, and Roche/Genentech. A.F. has received honoraria and/or travel grants from Bayer, Ipsen, and Pfizer. R.H.G. has participated in advisory boards for Ipsen and Pfizer and has received travel grants from Ipsen and Pfizer. A.G. has received honoraria and/or travel grants from Bayer, Novartis, and Pfizer. M.S. participated in advisory boards for AVEO, BMS, Eisai, EUSA Pharma, Exelixis, Ipsen, Novartis, Peloton, Pfizer, and Roche/Genentech, has received travel grants from Bayer, BMS, Eisai, Ipsen, Novartis, and Pfizer, and has received research grants from AVEO, BMS, Eisai, Exelixis, Ipsen, Novartis, Pfizer, and Roche/Genentech. The International Kidney Cancer Coalition (IKCC) receives grants from Global Offices of Ipsen/Exelixis, Merck/MDS, BMS, Pfizer, Novartis, and Eisai. T.G., T.D., M.P., H.R.D., K.A.G., C.v.F., and A.M. declare no competing interests. Publisher Copyright: © 2018, Macmillan Publishers Ltd., part of Springer Nature.
(Peer reviewed)